Citadel Advisors
GLMD icon

Citadel Advisors’s Galmed Pharmaceuticals GLMD Stock Holding History

Citadel Advisors’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.3K Buy
10,856
+9,433
+663% +$47K ﹤0.01% 13133
2026
Q1 		$5.5K Sell
1,423
-3,349
-70% -$18.1K ﹤0.01% 12812
2025
Q4 		$28.7K Sell
4,772
-1,540
-24% -$14.4K ﹤0.01% 12236
2025
Q3 		$71.2K Buy
+6,312
New +$81.1K ﹤0.01% 12027
2024
Q1 		– Sell
-117
Closed -$5.12K – 14886
2023
Q4 		$5.12K Sell
117
-304
-72% -$11.6K ﹤0.01% 13452
2023
Q3 		$25.1K Buy
+421
New +$44.7K ﹤0.01% 12432
2023
Q2 		– Sell
-28
Closed -$17.4K – 14660
2023
Q1 		$17.4K Buy
+28
New +$24K ﹤0.01% 13157
2022
Q4 		– Sell
-13
Closed -$6K – 15080
2022
Q3 		$6K Sell
13
-28
-68% -$19.1K ﹤0.01% 12346
2022
Q2 		$41K Buy
41
+32
+356% +$42.4K ﹤0.01% 12046
2022
Q1 		$20K Buy
+9
New +$20.4K ﹤0.01% 13238
2021
Q4 		– Sell
-20
Closed -$78K – 14165
2021
Q3 		$78K Sell
20
-7
-26% -$29.4K ﹤0.01% 13084
2021
Q2 		$120K Buy
+27
New +$117K ﹤0.01% 12743

Other funds holding GLMD

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's GLMD Position: Q2 2026 in Review

Citadel Advisors increased its Galmed Pharmaceuticals (GLMD) stake by 663% in Q2 2026, buying an estimated $47K and bringing the position to 10,856 shares worth $48.3K. The position accounts for ﹤0.01% of the portfolio, ranked #13133.

Citadel Advisors first reported a position in GLMD in Q2 2021 and has held it in 12 quarters since. The position peaked at $120K in Q2 2021. 11 funds tracked by Wall St. Rank hold GLMD as of Q2 2026.

  • Citadel Advisors held 10,856 shares of Galmed Pharmaceuticals worth $48.3K as of Q2 2026.
  • Citadel Advisors bought 9,433 Galmed Pharmaceuticals shares in Q2 2026, an estimated $47K.
  • Galmed Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13133 holding.
  • Citadel Advisors first reported a position in Galmed Pharmaceuticals in Q2 2021 and has held it in 12 quarters since.
  • Citadel Advisors's Galmed Pharmaceuticals position peaked at $120K in Q2 2021.
  • 11 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.